Lupin rolls out HIV drug Darunavir in US
Mumbai: Global pharma major, Lupin Limited, has announced the launch of Darunavir Tablets, 600 mg and 800 mg. The product is a generic equivalent of Prezista Tablets of Janssen Products, LP.
Darunavir Tablets are used in controlling HIV infection.
Darunavir Tablets, 600 mg and 800 mg (RLD Prezista) had estimated annual sales of USD 308 million in the U.S. (IQVIA MAT March 2023).
Read also: Lupin arm Novel Labs bags USFDA nod for Diazepam Rectal Gel
Medical Dialogues team had earlier reported that the company had received tentative approval from the United States Food and Drug Administration (USFDA) under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application for Dolutegravir, Emtricitabine and Tenofovir Alafenamide (DETAF) Tablets.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. The company invested 7.9% of its revenue in research and development in FY23. Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd